ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, active mutants of c-Abl, as well as the constitutively active Bcr-Abl fusion protein associated with chronic myelogenous leukemia, are both inhibited by linker proline substitutions that enhance interaction with the SH3 domain [33].